Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.44M, -0.8% YoY · Filed Aug 13, 2026
Arcadia Biosciences, Inc. (RKDA) files with the SEC under industry code 1311, Crude Petroleum & Natural Gas. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.4 million and a net loss of $6.3 million.
Revenue
$1.44M
-0.8% vs year-ago quarter
Net income
$-6.27M
-40.6% vs year-ago quarter
Operating cash flow
$-319,000
+84.3% vs year-ago quarter
Free cash flow
$-822,000
+62.8% vs year-ago quarter
EPS
$-2.09
+35.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.41M
+76.2% vs year-ago quarter
Net cash
$4.56M
Q4 FY2025
Operating margin
-80.2%
TTM
Company profile
- Industry
- Crude Petroleum & Natural Gas (SIC 1311)
- Listed as
- RKDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1469443
Other Crude Petroleum & Natural Gas companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $1.1M | $901,000 | $1.3M | $1.5M |
| Operating income | -$496,000 | -$779,000 | -$1.4M | -$1.2M | -$501,000 |
| Net income | -$6.3M | -$4.4M | -$1.3M | $856,000 | -$4.5M |
| Diluted EPS | -$2.09 | -$2.11 | -$0.97 | $0.62 | -$3.26 |
| Operating cash flow | -$319,000 | -$1.1M | -$822,000 | -$257,000 | -$2.0M |
| Free cash flow | — | — | -$822,000 | -$257,000 | -$2.0M |
| Total assets | $5.9M | $5.3M | $6.5M | $8.6M | $7.8M |
| Total liabilities | $5.3M | $2.4M | $2.4M | $3.1M | $3.3M |
| Stockholders' equity | $633,000 | $2.9M | $4.1M | $5.4M | $4.5M |
| Cash and investments | $4.2M | $3.7M | $4.6M | $5.9M | $4.4M |
| Total debt | — | — | $0 | $0 | $11,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 15, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 4, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| ARS | Annual report to shareholders | Aug 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Listing notice
|
Aug 10, 2026 | Aug 4, 2026 |
All 596 Arcadia Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.